Applus+ has acquired De.Testing, a leading medical device testing company in China, to enhance its capabilities and expand its presence in the growing medical device market.

Information on the Target

De.Testing, founded in 2019, is a prominent medical device testing company based in China. The company specializes in various sectors, including orthopaedics, dentistry, and medical device software. De.Testing is known for providing high-quality testing services and customizable technical solutions tailored to the needs of its clients. Additionally, it holds several prestigious accreditations, including the China Metrology Accreditation (CMA), the China National Accreditation Service for Conformity Assessment (CNAS), and the International Accreditation Service (IAS), enhancing its credibility in the medical device industry.

This acquisition not only bolsters Applus+'s service offerings but also positions it favorably in a rapidly expanding market that is increasingly demanding comprehensive testing solutions for medical devices.

Industry Overview in China

China's medical device industry has seen remarkable growth in recent years, driven by rising healthcare expenditure, an aging population, and increasing demand for advanced medical techn

View Source

Similar Deals

Adicon Holdings Limited Crown Bioscience Inc.

2026

Other Biotechnology & Medical Research (NEC) China
佳辰资本 辐联科技

2025

Other Proprietary & Advanced Pharmaceuticals China
磐霖资本 劲方医药

2025

Other Proprietary & Advanced Pharmaceuticals China
LaNova Medicines ProBio

2025

Other Bio Therapeutic Drugs China
Johnson & Johnson Ronovo Surgical

2025

Other Advanced Medical Equipment & Technology (NEC) China
晶泰控股 四维医学

2025

Other Telemedicine Services China

Applus+

invested in

De.Testing

in 2025

in a Other deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert